Galapagos says GSK starting trials of its new drug
BRUSSELS Feb 5 (Reuters) - Belgian biotech company Galapagos said on Tuesday that its partner GlaxoSmithKline (GSK) planned to start Phase II studies into a drug candidate to treat two auto-immune disorders.
Galapagos said in a statement that GSK would launch the studies for compound GSK2586184 in systemic lupus erythematosus (SLE) and chronic plaque psoriasis.
Galapagos is eligible to receive 34 million euros in additional milestones plus up to double-digit percentage royalties on global sales. It is the second selective JAK1 molecule discovered by Galapagos to enter Phase 2 studies.
- Israel pummels Gaza; Kerry steps up diplomatic push |
- Ukraine war crimes trials a step closer after Red Cross assessment
- South Korea ferry fugitive hid behind cabin wall, bags of cash at hand
- With sales sputtering, Apple's iPad looks to IBM alliance
- Five held in China food scandal probe, including head of Shanghai Husi Food